The Claim
Once-weekly subcutaneous retatrutide is associated with an 18.4-fold higher likelihood of achieving at least 15% body weight loss compared to placebo in adults with overweight, obesity, and/or type 2 diabetes, indicating that a high proportion of patients may reach clinically transformative weight loss thresholds.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People who get a weekly shot of a new medicine called retatrutide are about 18 times more likely to lose at least 15% of their body weight than those who get a placebo, which could mean a lot of them reach a weight loss level that really improves their health.
See the scientific wording
Once-weekly subcutaneous retatrutide is associated with a 18.4-fold higher likelihood of achieving ≥15% body weight loss compared to placebo in adults with overweight, obesity, and/or type 2 diabetes, indicating a high proportion of patients may reach clinically transformative weight loss thresholds.
What the research says
1 studyThis study found that people who got a weekly retatrutide shot lost a lot of weight — 18 times more likely to lose 15% or more of their body weight than those who got a placebo. That’s exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.